Crescita Financial Statements From 2010 to 2026

Stocks . Canada . 
Stock . Crescita Therapeutics
CTX Stock  CAD 0.49  0.02  4.26%   
Crescita Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Crescita Therapeutics' valuation are provided below:
Gross Profit
11.4 M
Profit Margin
0.0207
Market Capitalization
9.2 M
Enterprise Value Revenue
0.0419
Revenue
22.1 M
We have found one hundred twenty available fundamental signals for Crescita Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Crescita Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 18th of February 2026, Market Cap is likely to grow to about 14.4 M, while Enterprise Value is likely to drop about 3 M.

Crescita Therapeutics Total Revenue

14.92 Million

Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.

Crescita Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets25.3 M25 M18.3 M
Slightly volatile
Total Current Liabilities5.9 M6.3 M5.1 M
Slightly volatile
Other Liabilities203.6 K110.7 K212 K
Pretty Stable
Property Plant And Equipment Net2.9 M2.8 M1.2 M
Slightly volatile
Accounts Payable4.6 M5.7 M3.7 M
Slightly volatile
Cash8.8 M10.7 M6.4 M
Slightly volatile
Non Current Assets Total8.8 M7.4 M6.1 M
Slightly volatile
Cash And Short Term Investments9.7 M10.7 M7 M
Slightly volatile
Net Receivables2.8 M2 M2.1 M
Slightly volatile
Common Stock Shares Outstanding19.3 M22.2 M16.3 M
Slightly volatile
Short Term Investments2.6 K2.7 K527 K
Very volatile
Liabilities And Stockholders Equity25.3 M25 M18.3 M
Slightly volatile
Non Current Liabilities Total369.4 K388.8 K1.4 M
Very volatile
Inventory3.7 M4.7 M2.8 M
Slightly volatile
Other Current Assets347 K303.6 K242.9 K
Slightly volatile
Total Liabilities5.9 M5.4 M6.3 M
Pretty Stable
Property Plant And Equipment Gross6 M5.7 M2.1 M
Slightly volatile
Total Current Assets16.6 M17.6 M12.1 M
Slightly volatile
Accumulated Other Comprehensive Income1.2 M1.3 M1.1 M
Pretty Stable
Property Plant Equipment2.9 M2.8 M1.2 M
Slightly volatile
Short and Long Term Debt Total713.1 K750.6 K1.6 M
Pretty Stable
Long Term Debt Total312.1 K328.5 K1.2 M
Very volatile
Capital Surpluse8.9 M8.5 M2.7 M
Slightly volatile
Short and Long Term Debt1.2 M1.1 M937.8 K
Slightly volatile
Non Current Liabilities Other57.3 K60.3 K507.2 K
Slightly volatile
Cash And Equivalents10.7 M10.7 M9.8 M
Pretty Stable
Short Term Debt639.8 K844.2 K765.9 K
Very volatile
Intangible Assets1.5 M1.6 M6.6 M
Slightly volatile
Net Invested Capital16.2 M14.2 M18.5 M
Very volatile
Net Working Capital13.1 M11.3 M9.6 M
Slightly volatile
Common Stock Total Equity46.9 M52.4 M57.7 M
Slightly volatile
Capital Stock45.4 M47.4 M56.7 M
Slightly volatile
Capital Lease Obligations1.2 M959.1 K857.6 K
Slightly volatile
Long Term Investments269.8 K279.9 K330.4 K
Slightly volatile

Crescita Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.6 M937.4 K
Slightly volatile
Interest Expense55.6 K58.5 K178.6 K
Pretty Stable
Selling General Administrative10.5 M12.4 M9.1 M
Slightly volatile
Total Revenue14.9 M22.5 M11.2 M
Slightly volatile
Gross Profit9.1 M11 M6.7 M
Slightly volatile
Other Operating Expenses19.8 M26.2 M17.7 M
Slightly volatile
Research Development552.3 K581.4 K3.3 M
Slightly volatile
Cost Of Revenue5.8 M11.5 M4.5 M
Slightly volatile
Total Operating Expenses10.2 M11.5 M12.8 M
Slightly volatile
Interest Income239.5 K394.4 K173.9 K
Slightly volatile
Reconciled Depreciation1.5 M1.6 M1.3 M
Slightly volatile

Crescita Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation169.7 K162.9 K214.5 K
Slightly volatile
Begin Period Cash Flow7.9 M10.8 M5.9 M
Slightly volatile
Depreciation1.2 M1.6 M939.7 K
Slightly volatile
Capital Expenditures1.4 M1.4 M327.8 K
Slightly volatile
End Period Cash Flow8.8 M10.7 M6.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.620.667.2149
Slightly volatile
Days Sales Outstanding34.9536.79143
Slightly volatile
Stock Based Compensation To Revenue0.01010.01060.1054
Slightly volatile
Capex To Depreciation0.820.780.2927
Slightly volatile
EV To Sales0.150.166.7442
Slightly volatile
Inventory Turnover1.182.221.3083
Slightly volatile
Days Of Inventory On Hand313171341
Slightly volatile
Payables Turnover0.941.80.9636
Slightly volatile
Sales General And Administrative To Revenue0.60.632.7336
Slightly volatile
Research And Ddevelopement To Revenue0.0360.03793.3337
Slightly volatile
Capex To Revenue0.07310.06960.0349
Very volatile
Cash Per Share0.40.430.3854
Slightly volatile
Days Payables Outstanding200210903
Slightly volatile
Intangibles To Total Assets0.08710.09170.2748
Slightly volatile
Current Ratio2.162.52.1226
Slightly volatile
Receivables Turnover10.7810.275.1922
Slightly volatile
Debt To Equity0.05760.06060.1928
Slightly volatile
Capex Per Share0.05810.05530.0159
Slightly volatile
Revenue Per Share0.570.910.5654
Slightly volatile
Interest Debt Per Share0.0510.05360.1135
Very volatile
Debt To Assets0.04180.0440.1244
Slightly volatile
Graham Number1.171.121.32
Slightly volatile
Operating Cycle197207475
Slightly volatile
Days Of Payables Outstanding200210903
Slightly volatile
Long Term Debt To Capitalization0.04620.04860.129
Slightly volatile
Total Debt To Capitalization0.05470.05760.1536
Slightly volatile
Debt Equity Ratio0.05760.06060.1928
Slightly volatile
Quick Ratio1.661.841.6265
Slightly volatile
Net Income Per E B T1.451.141.2086
Pretty Stable
Cash Ratio1.171.511.1339
Slightly volatile
Days Of Inventory Outstanding313171341
Slightly volatile
Days Of Sales Outstanding34.9536.79143
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.10.650.9873
Pretty Stable
Fixed Asset Turnover13.789.2911.633
Pretty Stable
Debt Ratio0.04180.0440.1244
Slightly volatile
Price Sales Ratio0.620.667.2149
Slightly volatile
Asset Turnover0.50.810.601
Slightly volatile
Gross Profit Margin0.460.440.5843
Slightly volatile

Crescita Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14.4 M12.9 M13.7 M
Slightly volatile
Enterprise Value3 M3.1 M8.7 M
Slightly volatile

Crescita Fundamental Market Drivers

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5 M-5.3 M
Total Revenue22.5 M14.9 M
Cost Of Revenue11.5 M5.8 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.63  0.60 
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue 0.07  0.07 
Revenue Per Share 0.91  0.57 
Ebit Per Revenue(0.15)(0.16)

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY